NCT03318939 2024-04-03Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion MutationSpectrum Pharmaceuticals, IncPhase 2 Terminated648 enrolled
NCT04044170 2020-11-17Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion MutationHanmi Pharmaceutical Company LimitedPhase 2 Terminated5 enrolled